Cargando…

Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer

PURPOSE: Although both intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) offer effective long-term disease control for localized prostate cancer (PCa), there are limited data directly comparing the 2 modalities. METHODS: The data from 334 patients treated with conventionally...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Alicia, Barsky, Andrew R., Both, Stefan, Christodouleas, John P., Deville, Curtiland, Tochner, Zelig A., Vapiwala, Neha, Maxwell, Russell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Particle Therapy Co-operative Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563661/
https://www.ncbi.nlm.nih.gov/pubmed/37823012
http://dx.doi.org/10.14338/IJPT-23-00002.1
_version_ 1785118381312049152
author Bao, Alicia
Barsky, Andrew R.
Both, Stefan
Christodouleas, John P.
Deville, Curtiland
Tochner, Zelig A.
Vapiwala, Neha
Maxwell, Russell
author_facet Bao, Alicia
Barsky, Andrew R.
Both, Stefan
Christodouleas, John P.
Deville, Curtiland
Tochner, Zelig A.
Vapiwala, Neha
Maxwell, Russell
author_sort Bao, Alicia
collection PubMed
description PURPOSE: Although both intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) offer effective long-term disease control for localized prostate cancer (PCa), there are limited data directly comparing the 2 modalities. METHODS: The data from 334 patients treated with conventionally fractionated (79.2 GyRBE in 44 fractions) PBT or IMRT were retrospectively analyzed. Propensity score matching was used to balance factors associated with biochemical failure-free survival (BFFS). Age, race, and comorbidities (not BFFS associates) remained imbalanced after matching. Univariable and covariate-adjusted multivariable (MVA) Cox regression models were used to determine if modality affected BFFS. RESULTS: Of 334 patients, 176 (52.7%) were included in the matched cohort with exact matching to National Comprehensive Cancer Network (NCCN) risk group. With a median follow-up time of 9.0 years (interquartile range [IQR]: 7.8-10.2 years), long-term BFFS was similar between the IMRT and PBT matched arms with 8-year estimates of 85% (95% CI: 76%-91%) and 91% (95% CI: 82%-96%, P = .39), respectively. On MVA, modality was not significantly associated with BFFS in both the unmatched (hazard ratio [HR] = 0.75, 95% CI: 0.35-1.63, P = .47) and matched (HR = 0.87, 95% CI: 0.33-2.33, P = .78) cohorts. Prostate cancer–specific survival (PCSS) and overall survival (OS) were also similar (P > .05). However, in an unmatched analysis, the PBT arm had significantly fewer incidences of secondary cancers within the irradiated field (0.6%, 95% CI: 0.0%-3.1% versus 4.5%, 95% CI: 1.8%-9.0%, P = .028). CONCLUSIONS: Both PBT and IMRT offer excellent long-term disease control for PCa, with no significant differences between the 2 modalities in BFFS, PCSS, and OS in matched patients. In the unmatched cohort, fewer incidences of secondary malignancy were noted in the PBT group; however, owing to overall low incidence of secondary cancer and imbalanced patient characteristics between the 2 groups, these data are strictly hypothesis generating and require further investigation.
format Online
Article
Text
id pubmed-10563661
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Particle Therapy Co-operative Group
record_format MEDLINE/PubMed
spelling pubmed-105636612023-10-11 Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer Bao, Alicia Barsky, Andrew R. Both, Stefan Christodouleas, John P. Deville, Curtiland Tochner, Zelig A. Vapiwala, Neha Maxwell, Russell Int J Part Ther Original Articles PURPOSE: Although both intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) offer effective long-term disease control for localized prostate cancer (PCa), there are limited data directly comparing the 2 modalities. METHODS: The data from 334 patients treated with conventionally fractionated (79.2 GyRBE in 44 fractions) PBT or IMRT were retrospectively analyzed. Propensity score matching was used to balance factors associated with biochemical failure-free survival (BFFS). Age, race, and comorbidities (not BFFS associates) remained imbalanced after matching. Univariable and covariate-adjusted multivariable (MVA) Cox regression models were used to determine if modality affected BFFS. RESULTS: Of 334 patients, 176 (52.7%) were included in the matched cohort with exact matching to National Comprehensive Cancer Network (NCCN) risk group. With a median follow-up time of 9.0 years (interquartile range [IQR]: 7.8-10.2 years), long-term BFFS was similar between the IMRT and PBT matched arms with 8-year estimates of 85% (95% CI: 76%-91%) and 91% (95% CI: 82%-96%, P = .39), respectively. On MVA, modality was not significantly associated with BFFS in both the unmatched (hazard ratio [HR] = 0.75, 95% CI: 0.35-1.63, P = .47) and matched (HR = 0.87, 95% CI: 0.33-2.33, P = .78) cohorts. Prostate cancer–specific survival (PCSS) and overall survival (OS) were also similar (P > .05). However, in an unmatched analysis, the PBT arm had significantly fewer incidences of secondary cancers within the irradiated field (0.6%, 95% CI: 0.0%-3.1% versus 4.5%, 95% CI: 1.8%-9.0%, P = .028). CONCLUSIONS: Both PBT and IMRT offer excellent long-term disease control for PCa, with no significant differences between the 2 modalities in BFFS, PCSS, and OS in matched patients. In the unmatched cohort, fewer incidences of secondary malignancy were noted in the PBT group; however, owing to overall low incidence of secondary cancer and imbalanced patient characteristics between the 2 groups, these data are strictly hypothesis generating and require further investigation. The Particle Therapy Co-operative Group 2023-05-18 /pmc/articles/PMC10563661/ /pubmed/37823012 http://dx.doi.org/10.14338/IJPT-23-00002.1 Text en ©Copyright 2023 The Author(s) https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed in accordance with Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ).
spellingShingle Original Articles
Bao, Alicia
Barsky, Andrew R.
Both, Stefan
Christodouleas, John P.
Deville, Curtiland
Tochner, Zelig A.
Vapiwala, Neha
Maxwell, Russell
Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
title Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
title_full Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
title_fullStr Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
title_full_unstemmed Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
title_short Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
title_sort case-matched outcomes of proton beam and intensity-modulated radiation therapy for localized prostate cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563661/
https://www.ncbi.nlm.nih.gov/pubmed/37823012
http://dx.doi.org/10.14338/IJPT-23-00002.1
work_keys_str_mv AT baoalicia casematchedoutcomesofprotonbeamandintensitymodulatedradiationtherapyforlocalizedprostatecancer
AT barskyandrewr casematchedoutcomesofprotonbeamandintensitymodulatedradiationtherapyforlocalizedprostatecancer
AT bothstefan casematchedoutcomesofprotonbeamandintensitymodulatedradiationtherapyforlocalizedprostatecancer
AT christodouleasjohnp casematchedoutcomesofprotonbeamandintensitymodulatedradiationtherapyforlocalizedprostatecancer
AT devillecurtiland casematchedoutcomesofprotonbeamandintensitymodulatedradiationtherapyforlocalizedprostatecancer
AT tochnerzeliga casematchedoutcomesofprotonbeamandintensitymodulatedradiationtherapyforlocalizedprostatecancer
AT vapiwalaneha casematchedoutcomesofprotonbeamandintensitymodulatedradiationtherapyforlocalizedprostatecancer
AT maxwellrussell casematchedoutcomesofprotonbeamandintensitymodulatedradiationtherapyforlocalizedprostatecancer